Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year




Date of IPO


Market Cap


About Kubota Pharmaceutical Holdings

Kubota Pharmaceutical Holdings (TYO: 4596) identifies and develops therapeutics to treat ophthalmic disorders customers worldwide. It is based in Tokyo, Japan.

Kubota Pharmaceutical Holdings Headquarter Location

Kasumigaseki Tokyu Building 4F 3-7-1 Kasumigaseki, Chiyoda-ku

Tokyo, 100-0013,


+81 3 6550 8928

Latest Kubota Pharmaceutical Holdings News

Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Device

Nov 29, 2021

November 29, 2021 11:30 AM Eastern Standard Time SEATTLE--( BUSINESS WIRE )--Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper was co-authored by Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision, along with collaborators from the Manhattan Vision Associates / Institute for Vision Research (MVA) in New York City, and details the study results of axial length and choroidal thickness changes following short-term peripheral myopic defocus in normal adult subjects. In this study, a total of 20 subjects enrolled and watched a full-field projected movie four meters away for four hours in the morning wearing corrected spectacle lenses for distance vision in both eyes. The right eye was peripherally defocused and tested with a Fresnel lens overlay of +3.50D with a central clear aperture of 11.5 mm (correlating to a clear central visual field of approximately 23 degrees), and the left eye was tested with no Fresnel lens overlay. Additional defocus sessions were conducted in 10 of these subjects with +5.00D of peripheral defocus in the right eye. Axial length and subfoveal choroidal thickness were measured and compared between the test (right) and control (left) eyes. The results demonstrated that short-term peripheral myopic defocus significantly inhibited axial elongation in adult humans, while no significant changes were observed in choroidal thickness. The paper, titled “Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel ‘press-on’ lenses in humans,” is available in the online publication, Scientific Reports, at . Scientific Reports, published by Springer Nature, is an open-access, peer-reviewed journal publishing original research from across all areas of the natural sciences, psychology, medicine, and engineering. It focuses only research that is scientifically robust, original, and of the highest quality, reviewed by its own extensive network of expert peers. In 2017, Scientific Reports became the largest journal in the world, overtaking PLOS ONE in the number of research articles published. *1 Dr. Kubota stated, “We are thrilled this paper to be in Scientific Reports and feel that the mechanism of Kubota Glass technology is now being recognized as the world-class innovation it is. Our continuous research will provide stronger scientific evidence to support Kubota Glass technology and expand our business opportunities in many countries.” About Kubota Glass™ Technology Kubota Glass technology works to reduce the increase in axial length associated with myopia by using myopically-defocused images on the peripheral visual field to stimulate the retina. Peripheral myopic defocus is already in use in the US with a contact lens, “MiSight® 1 day” by CooperVision, which is U.S. Food and Drug Administration (FDA) approved to slow the progression of myopia. Kubota Glass seeks to reduce the progression of myopia by stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities. About Kubota Vision Inc. Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. ; “Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions. Contacts Yumiko Hamanaka

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Kubota Pharmaceutical Holdings Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kubota Pharmaceutical Holdings Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.